CV

CV Sciences IncOOTC CVSI Stock Report

Last reporting period 30 Jun, 2024

Updated 15 Nov, 2024

Last price

Market cap $B

0.008

Micro

Exchange

OOTC - OTC

CVSI Stock Analysis

CV

Uncovered

CV Sciences Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-34/100

Low score

Market cap $B

0.008

Dividend yield

Shares outstanding

150.1 B

CV Sciences, Inc. is a life science company. The Company operates through two business segments, namely consumer product and specialty pharmaceutical. The consumer product segment is focused on developing, manufacturing, marketing and selling plant-based dietary supplements and hemp-based cannabidiol (CBD) products to a range of market sectors. The specialty pharmaceutical segment is focused on developing and commercializing CBD-based therapeutics. It also develops, manufactures, markets and sells plant-based dietary supplements and CBD products under brands, including PlusCBD, PlusCBD Pet, ProCBD, Happy Lane, ProCBD, CV Acute, CV Defense and PlusCBD Pet in the healthcare market sector, including nutraceutical, beauty care, specialty foods and pet products. PlusCBD's line of products include softgel, tinctures, topicals, and gummies. PlusCBD Pet brand offer all the hemp extract just for cats and dogs. ProCBD brand are available through health practitioners.

View Section: Eyestock Rating